{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:18:39Z","timestamp":1760015919834,"version":"3.41.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"9-10","license":[{"start":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T00:00:00Z","timestamp":1458259200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Fundac\u00e3o para a Ci\u00eancia e a Tecnologia (FCT, Portugal)","award":["SFHR\/BD\/84936\/2012"],"award-info":[{"award-number":["SFHR\/BD\/84936\/2012"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chromatographia"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s10337-016-3063-7","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T19:20:21Z","timestamp":1458328821000},"page":"581-590","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["HPLC\u2013DAD Method for the Quantification of Carbamazepine, Oxcarbazepine and their Active Metabolites in HepaRG Cell Culture Samples"],"prefix":"10.1007","volume":"79","author":[{"given":"Ana","family":"Ferreira","sequence":"first","affiliation":[]},{"given":"M\u00e1rcio","family":"Rodrigues","sequence":"additional","affiliation":[]},{"given":"Am\u00edlcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[]},{"given":"Gilberto","family":"Alves","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2016,3,18]]},"reference":[{"key":"3063_CR1","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.addr.2011.12.003","volume":"64","author":"C Zhang","year":"2012","unstructured":"Zhang C, Kwan P, Zuo Z, Baum L (2012) The transport of antiepileptic drugs by p-glycoprotein. Adv Drug Deliv Rev 64:930\u2013942","journal-title":"Adv Drug Deliv Rev"},{"key":"3063_CR2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1528-1167.2011.03391.x","volume":"53","author":"AS Galanopoulou","year":"2012","unstructured":"Galanopoulou AS, Buckmaster PS, Staley KJ et al (2012) Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia 53:571\u2013582","journal-title":"Epilepsia"},{"key":"3063_CR3","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1046\/j.1472-8206.2001.00055.x","volume":"15","author":"E Perucca","year":"2001","unstructured":"Perucca E (2001) Clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fundam Clin Pharmacol 15:405\u2013417","journal-title":"Fundam Clin Pharmacol"},{"key":"3063_CR4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.yebeh.2009.02.030","volume":"15","author":"D Schmidt","year":"2009","unstructured":"Schmidt D (2009) Drug treatment of epilepsy: options and limitations. Epilepsy Behav 15:56\u201365","journal-title":"Epilepsy Behav"},{"key":"3063_CR5","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.seizure.2010.10.027","volume":"19","author":"MJ Brodie","year":"2010","unstructured":"Brodie MJ (2010) Antiepileptic drug therapy the story so far. Seizure 19:650\u2013655","journal-title":"Seizure"},{"key":"3063_CR6","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.addr.2011.11.006","volume":"64","author":"M Bialer","year":"2012","unstructured":"Bialer M (2012) Chemical properties of antiepileptic drugs (AEDs). Adv Drug Deliv Rev 64:887\u2013895","journal-title":"Adv Drug Deliv Rev"},{"issue":"Suppl 2","key":"3063_CR7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/epi.12185","volume":"54","author":"DF Weaver","year":"2013","unstructured":"Weaver DF (2013) Design of innovative therapeutics for pharmacoresistant epilepsy: challenges and needs. Epilepsia 54(Suppl 2):56\u201359","journal-title":"Epilepsia"},{"issue":"Suppl 2","key":"3063_CR8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/epi.12191","volume":"54","author":"DF Weaver","year":"2013","unstructured":"Weaver DF, Pohlmann-Eden B (2013) Pharmacoresistant epilepsy: unmet needs in solving the puzzle(s). Epilepsia 54(Suppl 2):80\u201385","journal-title":"Epilepsia"},{"key":"3063_CR9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/2042098611411127","volume":"2","author":"JA French","year":"2011","unstructured":"French JA, Gazzola DM (2011) New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety? Ther Adv Drug Saf 2:141\u2013158","journal-title":"Ther Adv Drug Saf"},{"key":"3063_CR10","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1021\/jm980627g","volume":"42","author":"J Benes","year":"1999","unstructured":"Benes J, Parada A, Figueiredo AA et al (1999) Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b, f]azepine-5-carboxamide derivatives. J Med Chem 42:2582\u20132587","journal-title":"J Med Chem"},{"key":"3063_CR11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/00044011-200424040-00001","volume":"24","author":"G Flesch","year":"2004","unstructured":"Flesch G (2004) Overview of the clinical pharmacokinetics of oxcarbazepine. Clin Drug Investig 24:185\u2013203","journal-title":"Clin Drug Investig"},{"key":"3063_CR12","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/FTD.0b013e3181e5c855","volume":"32","author":"G Alves","year":"2010","unstructured":"Alves G, Fortuna A, Sousa J et al (2010) Enantioselective assay for therapeutic drug monitoring of eslicarbazepine acetate: no interference with carbamazepine and its metabolites. Ther Drug Monit 32:512\u2013516","journal-title":"Ther Drug Monit"},{"key":"3063_CR13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10072-006-0663-2","volume":"27","author":"F Albani","year":"2006","unstructured":"Albani F, Baruzzi A (2006) Oxcarbazepine long-term treatment retention in patients switched over from carbamazepine. Neurol Sci 27:173\u2013175","journal-title":"Neurol Sci"},{"key":"3063_CR14","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1592\/phco.28.10.1211","volume":"28","author":"II Vaisleib","year":"2008","unstructured":"Vaisleib II, Neft RA (2008) Overnight transition from carbamazepine to oxcarbazepine in children and adolescents. Pharmacotherapy 28:1211\u20131214","journal-title":"Pharmacotherapy"},{"key":"3063_CR15","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.seizure.2010.05.002","volume":"19","author":"SA Lee","year":"2010","unstructured":"Lee SA, Heo K, Kim WJ et al (2010) Clinical feasibility of immediate overnight switching from slow-release carbamazepine to oxcarbazepine in Korean patients with refractory partial epilepsy. Seizure 19:356\u2013358","journal-title":"Seizure"},{"key":"3063_CR16","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1017\/S0317167100034892","volume":"25","author":"A Guberman","year":"1998","unstructured":"Guberman A (1998) Monotherapy or polytherapy for epilepsy? Can J Neurol Sci 25:S3\u2013S8","journal-title":"Can J Neurol Sci"},{"issue":"Suppl 8","key":"3063_CR17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1528-1167.2009.02238.x","volume":"50","author":"JA French","year":"2009","unstructured":"French JA, Faught E (2009) Rational polytherapy. Epilepsia 50(Suppl 8):63\u201368","journal-title":"Epilepsia"},{"key":"3063_CR18","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2174\/1871527311312030015","volume":"12","author":"G Giussani","year":"2013","unstructured":"Giussani G, Beghi E (2013) Does mechanism of drug action matter to inform rational polytherapy in epilepsy? CNS Neurol Disord: Drug Targets 12:426\u2013435","journal-title":"CNS Neurol Disord: Drug Targets"},{"key":"3063_CR19","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1586\/ecp.12.10","volume":"5","author":"C Johannessen Landmark","year":"2012","unstructured":"Johannessen Landmark C, Patsalos PN (2012) Methodologies used to identify and characterize interactions among antiepileptic drugs. Expert Rev Clin Pharmacol 5:281\u2013292","journal-title":"Expert Rev Clin Pharmacol"},{"key":"3063_CR20","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/978-1-60761-688-7_20","volume":"640","author":"TB Andersson","year":"2010","unstructured":"Andersson TB (2010) The application of HepRG cells in evaluation of cytochrome P450 induction properties of drug compounds. Methods Mol Biol 640:375\u2013387","journal-title":"Methods Mol Biol"},{"key":"3063_CR21","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.pharma.2008.09.002","volume":"66","author":"A Guillouzo","year":"2008","unstructured":"Guillouzo A (2008) New perspectives in the use of human hepatocytes in the preclinical drug development process. Ann Pharm Fr 66:288\u2013295","journal-title":"Ann Pharm Fr"},{"key":"3063_CR22","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1124\/dmd.109.030197","volume":"38","author":"S Anth\u00e9rieu","year":"2010","unstructured":"Anth\u00e9rieu S, Chesn\u00e9 C, Li R et al (2010) Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells. Drug Metab Dispos 38:516\u2013525","journal-title":"Drug Metab Dispos"},{"key":"3063_CR23","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1124\/dmd.110.037721","volume":"39","author":"M Darnell","year":"2011","unstructured":"Darnell M, Schreiter T, Zeilinger K et al (2011) Cytochrome P450-dependent metabolism in HepaRG cells cultured in a dynamic three-dimensional bioreactor. Drug Metab Dispos 39:1131\u20131138","journal-title":"Drug Metab Dispos"},{"key":"3063_CR24","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2174\/138920008786485128","volume":"9","author":"RL Walsky","year":"2008","unstructured":"Walsky RL, Boldt SE (2008) In vitro cytochrome P450 inhibition and induction. Curr Drug Metab 9:928\u2013939","journal-title":"Curr Drug Metab"},{"key":"3063_CR25","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1023\/A:1007669411738","volume":"17","author":"VP Shah","year":"2000","unstructured":"Shah VP, Midha KK, Findlay JW et al (2000) Bioanalytical method validation\u2013a revisit with a decade of progress. Pharm Res 17:1551\u20131557","journal-title":"Pharm Res"},{"key":"3063_CR26","unstructured":"US Food and Drug Administration (2001) Guidance for Industry: bioanalytical method validation. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm070107.pdf . Accessed 15 Jun 2015"},{"key":"3063_CR27","unstructured":"European Medicines Agency (2011) Guideline on bioanalytical method validation. http:\/\/www.ema.europa.eu\/docs\/enGB\/documentlibrary\/Scientificguideline\/2011\/08\/WC500109686.pdf . Accessed 15 Jun 2015"},{"key":"3063_CR28","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1570-0232(02)00244-1","volume":"774","author":"AM Almeida","year":"2002","unstructured":"Almeida AM, Castel-Branco MM, Falc\u00e3o AC (2002) Linear regression for calibration lines revisited: weighting schemes for bioanalytical methods. J Chromatogr B Anal Technol Biomed Life Sci 774:215\u2013222","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"3063_CR29","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/j.1528-1157.2000.tb00111.x","volume":"41","author":"CL Deckers","year":"2000","unstructured":"Deckers CL, Czuczwar SJ, Hekster YA et al (2000) Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 41:1364\u20131374","journal-title":"Epilepsia"},{"key":"3063_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0003-2670(02)00980-7","volume":"472","author":"F Bugamelli","year":"2002","unstructured":"Bugamelli F, Sabbioni C, Mandrioli R et al (2002) Simultaneous analysis of six antiepileptic drugs and two selected metabolites in human plasma by liquid chromatography after solid-phase extraction. Anal Chim Acta 472:1\u201310","journal-title":"Anal Chim Acta"},{"key":"3063_CR31","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/jssc.201100099","volume":"34","author":"A Fortuna","year":"2011","unstructured":"Fortuna A, Bicker J, Alves G et al (2011) A chiral HPLC-UV method for the quantification of dibenz[b, f]azepine-5-carboxamide derivatives in mouse plasma and brain tissue: eslicarbazepine acetate, carbamazepine and main metabolites. J Sep Sci 34:1391\u20131401","journal-title":"J Sep Sci"},{"key":"3063_CR32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2174\/157015909788848884","volume":"7","author":"WR Garnett","year":"2009","unstructured":"Garnett WR, St Louis EK, Henry TR, Bramley T (2009) Transitional polytherapy: tricks of the trade for monotherapy to monotherapy AED conversions. Curr Neuropharmacol 7:83\u201395","journal-title":"Curr Neuropharmacol"},{"key":"3063_CR33","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2125.2005.02529.x","volume":"61","author":"E Perucca","year":"2006","unstructured":"Perucca E (2006) Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 61:246\u2013255","journal-title":"Br J Clin Pharmacol"},{"key":"3063_CR34","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/157015910792246254","volume":"8","author":"SI Johannessen","year":"2010","unstructured":"Johannessen SI, Landmark CJ (2010) Antiepileptic drug interactions-principles and clinical implications. Curr Neuropharmacol 8:254\u2013267","journal-title":"Curr Neuropharmacol"},{"key":"3063_CR35","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2165\/00003088-199631060-00005","volume":"31","author":"R Riva","year":"1996","unstructured":"Riva R, Albani F, Contin M, Baruzzi A (1996) Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations. Clin Pharmacokinet 31:470\u2013493","journal-title":"Clinical considerations. Clin Pharmacokinet"},{"key":"3063_CR36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1528-1167.2012.03671.x","volume":"54","author":"MJ Brodie","year":"2013","unstructured":"Brodie MJ, Mintzer S, Pack AM et al (2013) Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia 54:11\u201327","journal-title":"Epilepsia"},{"key":"3063_CR37","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0031-6997(24)01340-1","volume":"49","author":"JH Lin","year":"1997","unstructured":"Lin JH, Lu AY (1997) Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 49:403\u2013449","journal-title":"Pharmacol Rev"},{"key":"3063_CR38","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF03190200","volume":"15","author":"G Fabre","year":"1990","unstructured":"Fabre G, Combalbert J, Berger Y, Cano JP (1990) Human hepatocytes as a key in vitro model to improve preclinical drug development. Eur J Drug Metab Pharmacokinet 15:165\u2013171","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"3063_CR39","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1517\/17425255.2014.857402","volume":"10","author":"A Costa","year":"2014","unstructured":"Costa A, Sarmento B, Seabra V (2014) An evaluation of the latest in vitro tools for drug metabolism studies. Expert Opin Drug Metab Toxicol 10:103\u2013119","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3063_CR40","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/nrd1851","volume":"4","author":"LC Wienkers","year":"2005","unstructured":"Wienkers LC, Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825\u2013833","journal-title":"Nat Rev Drug Discov"},{"key":"3063_CR41","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1042\/bst0290135","volume":"29","author":"DF McGinnity","year":"2001","unstructured":"McGinnity DF, Riley RJ (2001) Predicting drug pharmacokinetics in humans from in vitro metabolism studies. Biochem Soc Trans 29:135\u2013139","journal-title":"Biochem Soc Trans"},{"key":"3063_CR42","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.tiv.2012.05.008","volume":"26","author":"S Anth\u00e9rieu","year":"2012","unstructured":"Anth\u00e9rieu S, Chesn\u00e9 C, Li R et al (2012) Optimization of the HepaRG cell model for drug metabolism and toxicity studies. Toxicol Vitr 26:1278\u20131285","journal-title":"Toxicol Vitr"},{"key":"3063_CR43","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00169485","volume":"337","author":"W Daniel","year":"1988","unstructured":"Daniel W, Netter KJ (1988) Metabolic interaction between imipramine and carbamazepine in vivo and in vitro in rats. Naunyn Schmiedebergs Arch Pharmacol 337:105\u2013110","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"3063_CR44","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1124\/jpet.102.047530","volume":"305","author":"AC Egnell","year":"2003","unstructured":"Egnell AC, Houston B, Boyer S (2003) In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. J Pharmacol Exp Ther 305:1251\u20131262","journal-title":"J Pharmacol Exp Ther"},{"key":"3063_CR45","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s00216-010-3673-0","volume":"397","author":"A Fortuna","year":"2010","unstructured":"Fortuna A, Sousa J, Alves G et al (2010) Development and validation of an HPLC-UV method for the simultaneous quantification of carbamazepine, oxcarbazepine, eslicarbazepine acetate and their main metabolites in human plasma. Anal Bioanal Chem 397:1605\u20131615","journal-title":"Anal Bioanal Chem"},{"key":"3063_CR46","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jchromb.2014.09.010","volume":"971","author":"A Ferreira","year":"2014","unstructured":"Ferreira A, Rodrigues M, Oliveira P et al (2014) Liquid chromatographic assay based on microextraction by packed sorbent for therapeutic drug monitoring of carbamazepine, lamotrigine, oxcarbazepine, phenobarbital, phenytoin and the active metabolites carbamazepine-10,11-epoxide and licarbazepine. J Chromatogr B Analyt Technol Biomed Life Sci 971:20\u201329","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"3063_CR47","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.phrs.2004.09.008","volume":"51","author":"L Franceschi","year":"2005","unstructured":"Franceschi L, Furlanut M (2005) A simple method to monitor plasma concentrations of oxcarbazepine, carbamazepine, their main metabolites and lamotrigine in epileptic patients. Pharmacol Res 51:297\u2013302","journal-title":"Pharmacol Res"},{"key":"3063_CR48","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/BF02492681","volume":"54","author":"GA Khoschsorur","year":"2001","unstructured":"Khoschsorur GA, Fr\u00fchwirth F, Halwachs-Baumann G (2001) Simple and rapid HPLC method for simultaneous determination of multiple antiepileptic drugs in human serum. Chromatographia 54:345\u2013349","journal-title":"Chromatographia"},{"key":"3063_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchromb.2013.02.026","volume":"925","author":"A Serralheiro","year":"2013","unstructured":"Serralheiro A, Alves G, Fortuna A et al (2013) First HPLC-UV method for rapid and simultaneous quantification of phenobarbital, primidone, phenytoin, carbamazepine, carbamazepine-10,11-epoxide, 10,11-trans-dihydroxy-10,11-dihydrocarbamazepine, lamotrigine, oxcarbazepine and licarbazepine in human plas. J Chromatogr B Anal Technol Biomed Life Sci 925:1\u20139","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"3063_CR50","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/jssc.201100789","volume":"35","author":"S Rani","year":"2012","unstructured":"Rani S, Malik AK, Singh B (2012) Novel micro-extraction by packed sorbent procedure for the liquid chromatographic analysis of antiepileptic drugs in human plasma and urine. J Sep Sci 35:359\u2013366","journal-title":"J Sep Sci"},{"key":"3063_CR51","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF02263831","volume":"36","author":"M Meyler","year":"1993","unstructured":"Meyler M, Kelly MT, Smyth MR (1993) New method for the determination of four antiepileptic drugs in human plasma by high performance liquid chromatography. Chromatographia 36:27\u201332","journal-title":"Chromatographia"},{"key":"3063_CR52","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4103\/2229-4708.72223","volume":"1","author":"S Pandey","year":"2010","unstructured":"Pandey S, Pandey P, Tiwari G, Tiwari R (2010) Bioanalysis in drug discovery and development. Pharm Methods 1:14\u201324","journal-title":"Pharm Methods"},{"key":"3063_CR53","unstructured":"Korfmacher WA (2011) Bioanalytical support for both in vitro and in vivo assays across drug discovery and drug development. Encyclopedia of Drug Metabolism and Interactions, vol 6, 1st edn. Wiley, pp 1\u201318"},{"key":"3063_CR54","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/bmc.594","volume":"20","author":"NR Srinivas","year":"2006","unstructured":"Srinivas NR (2006) Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations. Biomed Chromatogr 20:383\u2013414","journal-title":"Biomed Chromatogr"}],"container-title":["Chromatographia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10337-016-3063-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10337-016-3063-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10337-016-3063-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T21:05:58Z","timestamp":1748811958000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10337-016-3063-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,18]]},"references-count":54,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["3063"],"URL":"https:\/\/doi.org\/10.1007\/s10337-016-3063-7","relation":{},"ISSN":["0009-5893","1612-1112"],"issn-type":[{"type":"print","value":"0009-5893"},{"type":"electronic","value":"1612-1112"}],"subject":[],"published":{"date-parts":[[2016,3,18]]}}}